The estimated Net Worth of Hideki Garren is at least 901 千$ dollars as of 13 September 2023. Dr Garren owns over 2,000 units of Prothena plc stock worth over 41,860$ and over the last 4 years he sold PRTA stock worth over 0$. In addition, he makes 859,639$ as Chief Medical Officer at Prothena plc.
Dr has made over 12 trades of the Prothena plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of PRTA stock worth 49,800$ on 13 September 2023.
The largest trade he's ever made was exercising 12,000 units of Prothena plc stock on 15 March 2023 worth over 298,800$. On average, Dr trades about 3,625 units every 27 days since 2021. As of 13 September 2023 he still owns at least 2,000 units of Prothena plc stock.
You can see the complete history of Dr Garren stock trades at the bottom of the page.
Dr. Hideki Garren M.D., Ph.D. is the Chief Medical Officer at Prothena plc.
As the Chief Medical Officer of Prothena plc, the total compensation of Dr D at Prothena plc is 859,639$. There are 7 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of 3,341,640$.
Dr D is 56, he's been the Chief Medical Officer of Prothena plc since . There are 9 older and 13 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.
Hideki's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 12 years, insiders at Prothena plc have traded over 79,429,035$ worth of Prothena plc stock and bought 2,987,732 units worth 75,619,043$ . The most active insiders traders include Capital, Llc Eco R1、Co Plc Elan Corp Plc Elan S...、Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of 946,769$. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth 67,650$.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: